Novartis Raises 2026 Core Operating Income Guidance Following Q3 Results

Novartis reported Q3 2026 net sales of $14.52 billion, up from $13.91 billion a year earlier, while operating profit fell 59.11% to $1.84 billion. The decline was primarily driven by a $1.9 billion impairment charge related to del-desiran. The company raised its 2026 core operating income guidance and maintained its net sales growth outlook, citing sales growth and productivity gains that are helping offset generic competition and clinical trial setbacks.